Bacterial Vaginosis clinical trials

Explore recruiting bacterial vaginosis clinical trials.

Recruiting bacterial vaginosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bacterial Vaginosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, randomized, open label, non-inferiority study comparing the efficacy and safety of furazidin vaginal tablets and clindamycin vaginal cream in the local treatment of bacterial vaginosis

Italy, Czechia, Poland, Slovakia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II/III multi-centre, open-label, parallel group study to prove the non-inferiority of safety and efficacy of Metronidazole/Neomycin Sulfate/ Nystatin, 500mg/ 65.000UI/100.000UI pessaries (Antibiotice SA) versus Tergynan® vaginal tablets (Bouchara–Recordati Laboratories) in the treatment of specific and non-specific vaginitis

Romania

Phase II and Phase III (Integrated) EU CTIS Study details

Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial (FEMITRANS)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A Multicentre, Randomized Study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy, safety, and dose-response of a Live Biotherapeutic Product (BGY-1601-VT, vaginal tablet) as a first-line monotherapy in women with acute vaginal infection: a randomized, double-blind, placebo-controlled study

France, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Bacterial Vaginosis trials by city

Bacterial Vaginosis in Toronto Bacterial Vaginosis in Vancouver Bacterial Vaginosis in Montreal Bacterial Vaginosis in Calgary Bacterial Vaginosis in Edmonton Bacterial Vaginosis in Ottawa Bacterial Vaginosis in Winnipeg Bacterial Vaginosis in Quebec City Bacterial Vaginosis in Hamilton Bacterial Vaginosis in Kitchener Bacterial Vaginosis in London Bacterial Vaginosis in Halifax Bacterial Vaginosis in New York Bacterial Vaginosis in Los Angeles Bacterial Vaginosis in Chicago Bacterial Vaginosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease